Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**anti-Fba antibody** refers to an experimental antibody directed against the Fba peptide epitope derived from *Candida albicans* fructose-bisphosphate aldolase, a cell surface-associated fungal antigen studied as an immunotherapeutic target in candidiasis. In the published preclinical literature, the best-defined example is the murine IgM monoclonal antibody **E2-9**, which bound the Fba epitope on *C. albicans* and showed protective activity in mouse models of disseminated candidiasis after passive transfer. This is not an approved pharmaceutical product; rather, it is a research-stage anti-infective antibody concept associated with work from academic investigators studying vaccine and passive immunization approaches against invasive *Candida* infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-Fba antibody.